title: A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
abstract: Angiogenesis, the development of new blood vessels, is essential for tumour growth; this process is stimulated by the secretion of numerous growth factors including platelet derived growth factor (PDGF). PDGF signalling, through its receptor platelet derived growth factor receptor (PDGFR), is involved in vessel maturation, stimulation of angiogenesis and upregulation of other angiogenic factors, including vascular endothelial growth factor (VEGF). PDGFR is a promising target for anti-cancer therapy because it is expressed on both tumour cells and stromal cells associated with the vasculature. MLN0518 (tandutinib) is a potent inhibitor of type III receptor tyrosine kinases that demonstrates activity against PDGFRα/β, FLT3 and c-KIT. In this study a multi-parametric MRI and histopathological approach was used to interrogate changes in vascular haemodynamics, structural response and hypoxia in C6 glioma xenografts in response to treatment with MLN0518. The doubling time of tumours in mice treated with MLN0518 was significantly longer than tumours in vehicle treated mice. The perfused vessel area, number of alpha smooth muscle actin positive vessels and hypoxic area in MLN0518 treated tumours were also significantly lower after 10 days treatment. These changes were not accompanied by alterations in vessel calibre or fractional blood volume as assessed using susceptibility contrast MRI. Histological assessment of vessel size and total perfused area did not demonstrate any change with treatment. Intrinsic susceptibility MRI did not reveal any difference in baseline R2* or carbogen-induced change in R2*. Dynamic contrast-enhanced MRI revealed anti-vascular effects of MLN0518 following 3 days treatment. Hypoxia confers chemo- and radio-resistance, and alongside PDGF, is implicated in evasive resistance to agents targeted against VEGF signalling. PDGFR antagonists may improve potency and efficacy of other therapeutics in combination. This study highlights the challenges of identifying appropriate quantitative imaging response biomarkers in heterogeneous models, particularly considering the multifaceted roles of angiogenic growth factors.
authors: Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom. Jessica.Boult@icr.ac.uk
authors: Jessica K R
authors: JK
authors: Boult
authors: Jennifer
authors: J
authors: Terkelsen
authors: Simon
authors: S
authors: Walker-Samuel
authors: Daniel P
authors: DP
authors: Bradley
authors: Simon P
authors: SP
authors: Robinson
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003287:Contrast Media; D003952:Diagnostic Imaging / Q000379:methods*; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D023041:Xenograft Model Antitumor Assays
chemical_list: D014408:Biomarkers, Tumor; D003287:Contrast Media; D010879:Piperazines; D011799:Quinazolines; C464670:tandutinib
references: Int J Cancer. 2008 Apr 1;122(7):1548-56
references: 18033683
references: Biol Pharm Bull. 1994 Dec;17(12):1686-8
references: 7537574
references: Brain Pathol. 2010 May;20(3):527-38
references: 19832839
references: Magn Reson Med. 2010 Sep;64(3):914-21
references: 20806382
references: J Magn Reson Imaging. 2003 Apr;17(4):445-54
references: 12655584
references: Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):872-9
references: 17889267
references: Cancer Cell. 2009 Mar 3;15(3):220-31
references: 19249680
references: Eur J Cancer. 2012 Mar;48(4):409-15
references: 22226478
references: Science. 1997 Jul 11;277(5323):242-5
references: 9211853
references: Nature. 2000 Sep 14;407(6801):242-8
references: 11001067
references: Oncologist. 2009 May;14(5):478-88
references: 19411318
references: J Pathol. 2011 Nov;225(3):344-52
references: 21590769
references: Br J Cancer. 2012 Jun 5;106(12):1960-6
references: 22596237
references: Cancer Cell. 2002 Jun;1(5):421-32
references: 12124172
references: Magn Reson Med. 2004 Mar;51(3):533-41
references: 15004795
references: Curr Opin Investig Drugs. 2008 Jun;9(6):570-5
references: 18516756
references: Cancer Res. 1994 Sep 1;54(17):4564-8
references: 8062241
references: Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93
references: 16860996
references: Nat Rev Cancer. 2004 Oct;4(10):806-13
references: 15510161
references: Nat Rev Cancer. 2002 Jan;2(1):38-47
references: 11902584
references: Am J Pathol. 2002 Mar;160(3):985-1000
references: 11891196
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: J Cell Biol. 2001 Apr 30;153(3):543-53
references: 11331305
references: Physiol Rev. 1999 Oct;79(4):1283-316
references: 10508235
references: Genes Dev. 2009 Jun 1;23(11):1283-8
references: 19487569
references: Magn Reson Med. 2009 Aug;62(2):420-9
references: 19353661
references: Br J Cancer. 2007 Jan 29;96(2):189-95
references: 17211479
references: Leukemia. 2006 Jan;20(1):1-8
references: 16281069
references: Br J Cancer. 2010 May 25;102(11):1555-77
references: 20502460
references: Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1470-6
references: 18538948
references: Development. 1998 May;125(9):1591-8
references: 9521897
references: J Clin Invest. 2003 Oct;112(8):1142-51
references: 14561699
references: Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52
references: 2845420
references: Cancer Res. 1992 Jun 1;52(11):3213-9
references: 1317261
references: Br J Cancer. 2005 May 9;92(9):1599-610
references: 15870830
references: Magn Reson Med. 1994 Dec;32(6):749-63
references: 7869897
references: Magn Reson Imaging. 2009 Apr;27(3):377-84
references: 18814988
references: Int J Cancer. 2012 Mar 15;130(6):1284-93
references: 21469141
references: Adv Cancer Res. 1985;43:175-203
references: 2581424
references: Am J Pathol. 2003 Apr;162(4):1083-93
references: 12651601
references: Nat Cell Biol. 2005 Sep;7(9):870-9
references: 16113679
references: Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41
references: 11395851